Loading news...
Thrivent Financial for Lutherans increased its position in Olin Corporation (NYSE: OLN) by 6.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,639,624 shares of the specialty chemicals company's stock after buying an additional 105,484 shares during the quarter. Thrivent
OLN swings to a Q4 loss as revenues slip amid customer destocking and maintenance turnarounds, with management warning Q1 EBITDA will fall.
Olin Corporation (NYSE: OLN - Get Free Report) has been given a consensus recommendation of "Hold" by the seventeen research firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating, two have given a buy rating and one has given
Olin (NYSE: OLN) executives detailed a fourth-quarter 2025 performance that fell "significantly below" internal expectations, citing operational disruptions, supply constraints, and a late-quarter drop in chlorine pipeline demand. On the company's earnings call, President and CEO Ken Lane and CFO Todd Slater said management is prioritizing cash generation, cost control, and a "value-first" commercial strategy as
Olin Corporation (OLN) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Olin (OLN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Olin (OLN) came out with a quarterly loss of $0.58 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.09 per share a year ago.
Highlights Fourth quarter 2025 net loss of ($85.7) million, or ($0.75) per diluted share Quarterly adjusted EBITDA of $67.7 million Year-end 2025 net debt comparable to year-end 2024 CLAYTON, Mo., Jan. 29, 2026 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced financial results for the fourth quarter ended December 31, 2025.
Olin (OLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Olin (OLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bayforest Capital Ltd bought a new stake in shares of Olin Corporation (NYSE: OLN) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,795 shares of the specialty chemicals company's stock, valued at approximately $770,000. Other hedge funds have also
Olin Corporation (NYSE: OLN - Get Free Report)'s stock price gapped down before the market opened on Friday. The stock had previously closed at $22.56, but opened at $20.65. Olin shares last traded at $21.9770, with a volume of 1,030,708 shares trading hands. Olin News Summary Here are the key news stories impacting Olin this
Olin Corporation remains a "Buy" as shares trade at a compressed ~9x mid-cycle earnings, despite recent operational setbacks. The Q4 EBITDA miss is primarily due to one-time maintenance overruns at Freeport; operations have since normalized, but capex may need to rise to sustainable levels. Demand headwinds persist, especially from weak Chinese and U.S. construction, with 2026 results expected to be flat or slightly lower versus 2025.
OLN cuts Q4 2025 adjusted EBITDA outlook to about $67M after Freeport disruptions and softer pipeline chlorine demand hit results.
SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing IBI324 (Ollin R&D code:OLN324), a next-generation VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in over 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). OLN324's up to 60-fold higher anti-Ang2 potency together with a smaller protein format and a higher molar dose gives OLN324 a differentiated, first-line standard of care profile.
CLAYTON, Mo., Jan. 8, 2026 /PRNewswire/ -- Olin Corporation (NYSE: OLN), today announced an updated outlook for the fourth quarter 2025.
CLAYTON, Mo., Jan. 6, 2026 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that on Friday, January 30, 2026, at 9:00 a.m.
OLN faces weak chemical demand, oversupply and high debt, pressuring margins, while rising copper costs and retailer destocking weigh on Winchester.
Olin Corp. has been battling subsidized imports. Olin recently announced a strategic partnership with one of the largest petrochemical companies in North and South America.
Shares of Olin Corporation (NYSE: OLN - Get Free Report) have received a consensus rating of "Hold" from the sixteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have issued a buy rating and one has